影响糖尿病黄斑水肿治疗效果的全身因素研究进展  

Systemic factors associated with treatment response in patients with diabetic macular edema

作　　者：姚婕 曹丹 曾运考 庄雪楠 张良 Yao Jie;Cao Dan;Zeng Yunkao;Zhuang Xuenan;Zhang Liang(Department of Ophthalmology,Guangdong Provincial People's Hospital,Guangdong Academy of Medical Sciences,Guangdong Eye Institute,Guangzhou 510080,China;Shantou University Medical College,Shantou 515041,China)

机构地区：[1]广东省人民医院(广东省医学科学院)眼科广东省眼病防治研究所,广州510080 [2]汕头大学医学院,汕头515041

出　　处：《中华眼底病杂志》2022年第3期253-256,共4页Chinese Journal of Ocular Fundus Diseases

基　　金：国家自然科学基金青年项目(81900866);白求恩·默克糖尿病研究基金(G2018030)。

摘　　要：糖尿病黄斑水肿(DME)是糖尿病患者视力下降甚至失明的主要原因。玻璃体腔注射抗血管内皮生长因子药物是目前DME的一线治疗手段,但患者个体全身因素的差异可能是导致部分患者治疗效果不佳的原因。年龄较大是DME治疗反应不良的预测因素,血糖控制、高血压、血脂异常、肾病及相关因素等对DME治疗效果的影响则有待进一步研究。明确全身因素对DME治疗反应的影响,对预测患者的治疗效果,提高DME治疗有效率有重要意义。Diabetic macular edema(DME)is the main cause of vision loss and even blindness in patients with diabetic retinopathy.Intravitreal anti-vascular endothelial factor therapy has become the gold standard management of DME.However,not all eyes response optimally to common management of DME,which could be due to the differences of individual factors.Increasing age could be the predictive factors for poor outcome.The influence of glycemic control,hypertension,dyslipidemia,chronic kidney disease and relative factors on treatment response require further investigation.Identifying the systemic factors that influence the treatment response of DME can provide the evidence to predict the prognosis of DME,and improve the efficacy of clinical treatment.

关 键 词：糖尿病视网膜病变 黄斑水肿 治疗 预后 综述 

分 类 号：R774.5[医药卫生—眼科]